Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA.

Abstract:

BACKGROUND:In 1999, the American Academy of Pediatrics (AAP) and the U.S. Public Health Service (USPHS) issued a joint statement on thimerosal in vaccines, which advised clinicians to temporarily postpone the first dose of hepatitis B vaccine for infants born to hepatitis B surface antigen (HBsAg)-negative women. In 2005, the Advisory Committee on Immunization Practices (ACIP) updated the strategy to improve prevention of perinatal and early childhood hepatitis B virus (HBV) transmission. OBJECTIVES:To evaluate the progress in hepatitis B birth dose vaccination coverage in birth year cohort from 1998 to 2007 and assess the impact of changes in ACIP recommendations on the birth dose coverage. METHODS:Birth year cohort study of hepatitis B birth dose vaccination status of 200,865 children aged 19-35 months in the United States and by selected socio-demographic factors; percentage increases of hepatitis B birth dose vaccination coverage between two consecutive birth year cohorts from 1998 to 2007. RESULTS:From 1998 to 1999, hepatitis B birth dose vaccination coverage declined overall in the United States and among selected socio-demographic groups (P<0.001). Conversely, from 1999 to 2007 hepatitis B birth dose vaccination coverage increased significantly by birth year cohort (P<0.001), from approximately 30% in the 1999 birth year cohort to approximately 60% in the 2007 birth year cohort. The first significant increase in hepatitis B birth dose vaccination coverage occurred from 2000 to 2001 birth year cohort. Coverage increases ranged from 8.4% to 11.9% (P<0.001) in the U.S. and across all socio-demographic strata. The second largest increase in hepatitis B birth dose vaccination coverage occurred from 2005 to 2006 birth year cohort in the U.S. and among almost all socio-demographic strata, ranging from 5.6% to 8.7% (P<0.001). Forty-one of the 50 states and the District of Columbia (80%) in the U.S. had increases in hepatitis B birth dose vaccination coverage from 2005 to 2006 birth year cohort. CONCLUSIONS:The United States has made substantial progress in increasing hepatitis B birth dose vaccination and recovered from coverage declines associated with temporary postponement of the birth dose in 1999. The hepatitis B birth dose coverage in the U.S. remains substantially below the Healthy People 2020 target of 85%.

journal_name

Vaccine

journal_title

Vaccine

authors

Zhao Z,Murphy TV,Jacques-Carroll L

doi

10.1016/j.vaccine.2011.10.076

subject

Has Abstract

pub_date

2011-12-09 00:00:00

pages

14-20

issue

1

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(11)01713-0

journal_volume

30

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.

    abstract:BACKGROUND:Despite its high worldwide morbidity and mortality, there is yet no licensed vaccine for shigellosis. We reported the safety and immunogenicity of Shigella O-specific polysaccharide-protein conjugates in adults and young children and efficacy of Shigella sonnei conjugate in young adults. METHODS:A double-bl...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2009.12.050

    authors: Passwell JH,Ashkenazi S,Banet-Levi Y,Ramon-Saraf R,Farzam N,Lerner-Geva L,Even-Nir H,Yerushalmi B,Chu C,Shiloach J,Robbins JB,Schneerson R,Israeli Shigella Study Group.

    更新日期:2010-03-02 00:00:00

  • Synthetic gonadotrophin-releasing hormone (GnRH) vaccines incorporating GnRH and synthetic T-helper epitopes.

    abstract::A vaccine against the gonadotrophin-releasing hormone (GnRH) is being developed as an immunological method for treatment of prostatic hypertrophy, based on the observation that active immunization against GnRH leads to the production of anti-GnRH antibodies which results in the shrinkage of the prostate gland. We have...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90077-b

    authors: Sad S,Chauhan VS,Arunan K,Raghupathy R

    更新日期:1993-01-01 00:00:00

  • Fusion of antigen to Fas-ligand in a DNA vaccine enhances immunogenicity.

    abstract::DNA vaccines have considerable potential for the prophylaxis and therapy of a range of diseases, but their potential has not been realised largely due to poor immunogenicity. Fas ligand is a pro-apoptotic molecule, able to induce death of Fas expressing cells. We describe the construction of a DNA vaccine encoding a c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.11.059

    authors: Nimal S,Thomas MS,Heath AW

    更新日期:2007-03-08 00:00:00

  • Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.

    abstract::Simpler schedules for human papillomavirus (HPV) vaccine delivery could improve vaccine coverage and the effectiveness of cervical cancer prevention. The objective of this study was to systematically review evidence about the effects of two-dose compared with three-dose schedules for human papillomavirus (HPV) vaccine...

    journal_title:Vaccine

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.vaccine.2017.03.096

    authors: D'Addario M,Redmond S,Scott P,Egli-Gany D,Riveros-Balta AX,Henao Restrepo AM,Low N

    更新日期:2017-05-19 00:00:00

  • Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: an immunoinformatics study.

    abstract::An immuno-informatics study was conducted to determine possible pre-existing T cellular immunity to the recently emerged swine-origin triple reassortant H3N2 variant (S-OtrH3N2v-2011) which acquired the matrix gene of influenza A (H1N1)pdm09. Given the genetic origin of S-OtrH3N2v-2011, our study focused on the hemagg...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.07.054

    authors: Duvvuri VR,Marchand-Austin A,Eshaghi A,Patel SN,Low DE,Gubbay JB

    更新日期:2012-09-14 00:00:00

  • Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine.

    abstract::A varicella-zoster virus (VZV) seropositive individual was immunized with 100 micrograms of purified VZV TgpI-511 glycoprotein subunit antigen formulated with monophosphoryl lipid A. Serum samples were obtained during a 40-day period post-immunization (PI) and analysed by immunoprecipitation and virus neutralization t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)00073-v

    authors: Vafai A

    更新日期:1995-10-01 00:00:00

  • US Military contributions to the global response to pandemic chikungunya.

    abstract::Chikungunya virus, transmitted by mosquitoes to man, causes an acute illness characterized by fever, rash and striking joint symptoms. US Military investigators developed, manufactured at The Salk Institute-Government Services Division (TSI-GSD), and tested the live, attenuated Chikungunya Vaccine TSI-GSD-218. The man...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.08.025

    authors: Hoke CH Jr,Pace-Templeton J,Pittman P,Malinoski FJ,Gibbs P,Ulderich T,Mathers M,Fogtman B,Glass P,Vaughn DW

    更新日期:2012-10-19 00:00:00

  • Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.

    abstract::Liquid vaccine dosage forms have limited stability and require refrigeration during their manufacture, distribution and storage. In contrast, solid vaccine dosage forms, produced by for example spray drying, offer improved storage stability and reduced dependence on cold-chain facilities. This is advantageous for mass...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.04.055

    authors: Thakur A,Ingvarsson PT,Schmidt ST,Rose F,Andersen P,Christensen D,Foged C

    更新日期:2018-05-31 00:00:00

  • Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.

    abstract::Because of delays in the manufacturing of the 2000-2001, trivalent inactivated influenza vaccine in the US, there were concerns that there might be shortages of vaccine supply in the US. Therefore, we conducted a prospective, randomized, open-label, multicenter trial at six academic medical centers in the US, to evalu...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(01)00440-6

    authors: Treanor J,Keitel W,Belshe R,Campbell J,Schiff G,Zangwill K,Wolff M,Klimov A,Levandowski R,Lambert L

    更新日期:2002-01-15 00:00:00

  • Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

    abstract::In this proof-of-concept study we report the use of <15 nm, water soluble, inorganic nanoparticles as a vaccine delivery system for a blood stage malaria vaccine. The recombinant malarial antigen, Merozoite Surface Protein 1 (rMSP1) of Plasmodium falciparum served as the model vaccine. The rMSP1 was covalently conjuga...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.09.070

    authors: Pusic K,Xu H,Stridiron A,Aguilar Z,Wang A,Hui G

    更新日期:2011-11-08 00:00:00

  • Development of an attenuated strain of chikungunya virus for use in vaccine production.

    abstract::An attenuated chikungunya (CHIK) virus clone was developed for production of a live vaccine for human use. CHIK strain 15561 was subjected to 18 plaque-to-plaque passages in MRC-5 cultures before CHIK 181/clone 25 was selected as vaccine seed based on homogeneous small plaque size, suckling mouse avirulence, reduced m...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(86)90003-4

    authors: Levitt NH,Ramsburg HH,Hasty SE,Repik PM,Cole FE Jr,Lupton HW

    更新日期:1986-09-01 00:00:00

  • Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?

    abstract::B. pseudomallei is the cause of melioidosis, a serious an often fatal disease of humans and animals. The closely related bacterium B. mallei, which cases glanders, is considered to be a clonal derivative of B. pseudomallei. Both B. pseudomallei and B. mallei were evaluated by the United States and the former USSR as p...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2017.03.022

    authors: Titball RW,Burtnick MN,Bancroft GJ,Brett P

    更新日期:2017-10-20 00:00:00

  • Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.

    abstract::Using HIV-1 envelope protein (Env)-based immunogens that closely mimic the conformation of functional HIV-1 Envs and represent the isolates prevalent in relevant geographical region is considered a rational approach towards developing HIV vaccine. We recently reported that like clade B Env, JRFL, membrane bound Indian...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.01.081

    authors: Shrivastava T,Samal S,Tyagi AK,Goswami S,Kumar N,Ozorowski G,Ward AB,Chakrabarti BK

    更新日期:2018-03-14 00:00:00

  • Toxicity assessment of Clostridium difficile toxins in rodent models and protection of vaccination.

    abstract::Clostridium difficile is the leading cause of hospital-acquired diarrhea, also known as C. difficile associated diarrhea. The two major toxins, toxin A and toxin B are produced by most C. difficile bacteria, but some strains, such as BI/NAP1/027 isolates, produce a third toxin called binary toxin. The precise biologic...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.11.026

    authors: Wang S,Rustandi RR,Lancaster C,Hong LG,Thiriot DS,Xie J,Secore S,Kristopeit A,Wang SC,Heinrichs JH

    更新日期:2016-03-04 00:00:00

  • Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.

    abstract::The vaccination of wild animals against rabies has been developed most extensively in Europe. Experiments have demonstrated the efficacy of a vaccinia-rabies recombinant virus administered by the oral route in foxes. The innocuity of this vaccine was tested in the target species as well as in several non-target wild a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(90)90129-a

    authors: Brochier B,Thomas I,Bauduin B,Leveau T,Pastoret PP,Languet B,Chappuis G,Desmettre P,Blancou J,Artois M

    更新日期:1990-04-01 00:00:00

  • Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine.

    abstract::Immunization with amyloid-beta (Abeta) peptide reduces amyloid load in animal studies and in humans; however clinical trials resulted in the development of a pro-inflammatory cellular response to Abeta. Apoptosis has been employed to stimulate humoral and Th2-biased cellular immune responses. Thus, we sought to invest...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.12.044

    authors: DaSilva KA,Brown ME,McLaurin J

    更新日期:2009-02-25 00:00:00

  • Immunisation with aluminium-containing vaccine of a child with itching nodule following previous vaccination.

    abstract::Vaccination of children with aluminium sensitisation against diphtheria and tetanus presents a problem, since vaccine without aluminium against these potentially serious infectious diseases is no longer available. This case report presents a 7-month-old boy who, after his second immunisation with DTaP-IPV, developed a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.03.013

    authors: Frederiksen MS,Tofte H

    更新日期:2004-11-15 00:00:00

  • Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

    abstract::Optimal protection against malaria may require induction of high levels of protective antibody and CD8(+) and CD4(+) T cell responses. In humans, malaria DNA vaccines elicit CD8(+) cytotoxic T cells (CTL) and IFNgamma responses as measured by short-term (ex vivo) ELISPOT assays, and recombinant proteins elicit antibod...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2004.01.031

    authors: Epstein JE,Charoenvit Y,Kester KE,Wang R,Newcomer R,Fitzpatrick S,Richie TL,Tornieporth N,Heppner DG,Ockenhouse C,Majam V,Holland C,Abot E,Ganeshan H,Berzins M,Jones T,Freydberg CN,Ng J,Norman J,Carucci DJ,Cohen J

    更新日期:2004-04-16 00:00:00

  • A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.

    abstract:BACKGROUND:HIV-1 specific cellular immunity plays an important role in controlling viral replication. In this first-in-human therapeutic vaccination study, a replication-defective HIV-1 vaccine (HIVAX) was tested in HIV-1 infected participants undergoing highly active antiretroviral therapy (HAART) to enhance anti-HIV ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2016.03.021

    authors: Tung FY,Tung JK,Pallikkuth S,Pahwa S,Fischl MA

    更新日期:2016-04-27 00:00:00

  • The biology of influenza viruses.

    abstract::The influenza viruses are characterized by segmented, negative-strand RNA genomes requiring an RNA-dependent RNA polymerase of viral origin for replication. The particular structure ofthe influenza virus genome and function of its viral proteins enable antigenic drift and antigenic shift. These processes result in vir...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.07.039

    authors: Bouvier NM,Palese P

    更新日期:2008-09-12 00:00:00

  • Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice.

    abstract::Streptococcus pneumoniae (pneumococcus) is responsible for significant morbidity and mortality in worldwide. After introduction of current pneumococcal vaccines, a marked decrease in the incidence of pneumococcal disease was observed. Unfortunately, serotype shifts in carriage and disease, including capsular switch an...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.073

    authors: Kim EH,Choi SY,Kwon MK,Tran TD,Park SS,Lee KJ,Bae SM,Briles DE,Rhee DK

    更新日期:2012-03-02 00:00:00

  • Laboratory and field evaluation of Schistosoma japonicum DNA vaccines in sheep and water buffalo in China.

    abstract::Vaccines are needed to control zoonotic Schistosoma japonicum infection and several vaccine candidates have now been identified. Two of these (Sj28GST and Sj23) have shown particular promise in sheep when injected with Freund's adjuvants. The objective of the present work was to find a vaccine formulation which may ha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00340-1

    authors: Shi F,Zhang Y,Ye P,Lin J,Cai Y,Shen W,Bickle QD,Taylor MG

    更新日期:2001-11-12 00:00:00

  • Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice.

    abstract::We created and produced a novel self-assembling nanoparticle platform for delivery of peptide epitopes that induces CD8(+) and CD4(+)T cells that are protective against Toxoplasma gondii infection. These self-assembling polypeptide nanoparticles (SAPNs) are composed of linear peptide (LP) monomers which contain two co...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.092

    authors: El Bissati K,Zhou Y,Dasgupta D,Cobb D,Dubey JP,Burkhard P,Lanar DE,McLeod R

    更新日期:2014-05-30 00:00:00

  • A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.

    abstract::A strategy to improve the immunogenicity of candidate vaccines is to trigger the innate immune system. Triggering of CD40 at the surface of dendritic cells (DC) is essential in the induction of an efficient immune response. Although CD40 agonist antibodies have been shown to be potent inducers of immune responses in e...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.05.028

    authors: Miconnet I,Pantaleo G

    更新日期:2008-07-29 00:00:00

  • Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

    abstract::Salmonellae are commonly isolated from dogs. The number of dogs infected with Salmonella spp. is surprisingly high and greater than the incidence of clinical disease would suggest. Salmonellosis is common in greyhound kennels. Morbidity can approach 100% in puppies and the mortality ranges to nearly 40%. To date, ther...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00516-3

    authors: McVey DS,Chengappa MM,Mosier DE,Stone GG,Oberst RD,Sylte MJ,Gabbert NM,Kelly-Aehle SM,Curtiss R

    更新日期:2002-02-22 00:00:00

  • Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties.

    abstract::Crystallization of inulin with alum forms a fine (1-2 micron) suspension of electron-dense ovoids; the alum is embedded in inulin particles, which are then converted to the immune stimulant polymorphic form, gamma inulin. This very stable hybrid preparation is termed Algammulin. Preferred conditions for its preparatio...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90063-c

    authors: Cooper PD,Steele EJ

    更新日期:1991-05-01 00:00:00

  • Inadequate response to intradermal hepatitis A vaccine.

    abstract::To assess the efficacy of the intradermal route of administration of hepatitis A vaccine we conducted a study in hospital laboratory workers. Forty-three volunteers were given three different combinations of intradermal and intramuscular hepatitis A vaccine and compared with 18 controls given intramuscular vaccine onl...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(94)90303-4

    authors: Brindle RJ,Morris CA,Berger R,Kurtz JB

    更新日期:1994-05-01 00:00:00

  • Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.

    abstract:PURPOSE:Meningococcal C conjugate vaccine was included in December 2000 in the Spanish childhood vaccination at 2, 4 and 6 months of age. In 2006, routine vaccination was modified to two doses at 2 and 4-6 months and a booster dose during the second year of age. Additionally, successive catch-up campaigns were launched...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.010

    authors: Garrido-Estepa M,León-Gómez I,Herruzo R,Cano R

    更新日期:2014-05-07 00:00:00

  • Leprosy vaccine: influence of dissolved oxygen levels on growth of a candidate strain (Mycobacterium w), and storage stability of the vaccine.

    abstract::The growth of Mycobacterium w, a candidate strain for leprosy vaccine in submerged culture, was inhibited by the presence of over 40% oxygen saturation in the medium. Intracellular levels of superoxide dismutase and catalase were very low in the beginning. However, under controlled oxygenation, these levels increased ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00022-x

    authors: Mukhopadhyay A,Panda AK,Pandey AK

    更新日期:1998-08-01 00:00:00

  • Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study.

    abstract:INTRODUCTION:We estimated influenza vaccine effectiveness (IVE) to prevent laboratory-confirmed influenza-related hospitalizations in patients 18 years old or older during the 2010-2011 influenza season. METHODS:We conducted a prospective case-control study in five hospitals, in Valencia, Spain. Study subjects were co...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2012.07.006

    authors: Puig-Barberà J,Díez-Domingo J,Arnedo-Pena A,Ruiz-García M,Pérez-Vilar S,Micó-Esparza JL,Belenguer-Varea A,Carratalá-Munuera C,Gil-Guillén V,Schwarz-Chavarri H

    更新日期:2012-08-24 00:00:00